Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced today the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be met. PEG-INTRON (peginterferon alpha-2b), is approved for the treatment of Hepatitis C and is marketed worldwide by Schering-Plough Corporation (SGP).

Speaking on behalf of DRC, Paul Kirkconnell, Managing Director, said: "DRC is very pleased to be working with Enzon Pharmaceuticals. We believe that PEG- INTRON is one of the most advanced medications to treat Hepatitis C on the market today." Kirkconnell added, "With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon."

About PEG-INTRON(R)

PEG-INTRON is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON(R) A, which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's license agreement with Schering-Plough, Schering-Plough holds an exclusive worldwide license to PEG-INTRON, and Enzon receives royalties on worldwide sales of PEG-INTRON. Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON. Enzon designed PEG-INTRON to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. PEG-INTRON is marketed worldwide by Schering-Plough and its affiliates.

About Drug Royalty Corporation, Inc. (DRC)

Drug Royalty Corporation ("DRC") is a privately held investment management company, focused on the healthcare industry, with over $1 billion under management. DRC currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing roya
'/>"/>

SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... entity to deal with for regulators. , ,In an editorial ... it, I observed that consolidation just like in the ... evolution and is critical for survival: , As a country, ... "revestiture". Revestiture is the industry's modern attempt to circle the ...
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... water main break Thursday at the Milwaukee County Grounds ... 37 companies in the Milwaukee County Research Parks Technology ... businesses in the incubator building were functioning despite the ... in the 137,000-square-foot Technology Innovation Center, said the center ...
Cached Biology Technology:Old bell system merging back together, but it's not the same 2Old bell system merging back together, but it's not the same 3Old bell system merging back together, but it's not the same 4
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... made concerning the possible inventory of molecules available ... Pizzarello, a research professor at Arizona State University, ... in a blazing fireball over California last year, ... meteorites. These findings suggest a far greater availability ...
... R.I. [Brown University] Although preeclampsia occurs in about ... cases. A report of new research, now in press ... how two distinct risk factors combine to affect the ... life-threatening pregnancy complication. The findings suggest there could be ...
... engineering capabilities that underpin the nuclear weapons stockpile stewardship ... laboratories are "healthy and vibrant," says a new report ... wrote the report found no problems with the quality ... the stockpile. However, the report identifies several issues that, ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Study details paired risk factors in preeclampsia 2Study details paired risk factors in preeclampsia 3New report reviews science and engineering quality at national security laboratories 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Antibody Diluent for IHC 125 ml...
Biology Products: